Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: Embodiments of the present disclosure provide systems and methods for a lightweight monitoring application with key performance indicators (KPI) reporting and management. The method may include displaying a page with a plurality of tiles on a user device. The tiles displayed on the page may include a plurality of key performance indicator (KPI) tiles and at least one of a report tile, a news tile and a collaboration tile. The method may retrieve metadata from an in-memory database, the metadata from the in-memory database may correspond to content displayed in at least one of the KPI tiles on the page. In response to an input from a user input apparatus selecting one of the tiles displayed on the page, the method may display additional details or controls for the selected tile.

Abstract: The invention relates to the discovery of a novel Chondroitinase Glycoproteins (CHASEGPs), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.

Abstract: An information handling system (IHS) troubleshooting system includes a customer IHS including a plurality of components. A customer management system in the customer IHS detects a failure in a managed system and, in response, immediately triggers a device snapshot of the customer IHS. At least one managed system in the customer IHS includes a device snapshot engine that, in response to the customer management system triggering the device snapshot of the customer IHS, immediately create the device snapshot of the customer IHS. A device snapshot storage in the customer IHS stores the device snapshot of the customer IHS. A snapshot communication engine in the customer IHS sends the device snapshot of the customer IHS over the network to a support IHS. The support IHS may load the device snapshot into a virtual IHS and manage the virtual IHS to replicate the failure detected in the managed system for troubleshooting.

Abstract: The invention provides for at least three processes for detecting the probability of abusive use of a message account for sending large amounts of unsolicited messages, such as spam, to other message accounts. For example, information provided at registration for a new message account can be processed to determine the likelihood of abusive use of that message account. Also, inbound messages can be processed to determine if the message account that sent the inbound message is abusing the use of that message account. Additionally, outbound messages can be processed to determine if the message account that is attempting to send an outbound message is abusing the use of that message account. Each of these three processes can operate separately or in any combination with each other to further improve the probability that abusive use of a message account will be detected promptly and accurately.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention provides for at least three processes for detecting the probability of abusive use of a message account for sending large amounts of unsolicited messages, such as spam, to other message accounts. For example, information provided at registration for a new message account can be processed to determine the likelihood of abusive use of that message account. Also, inbound messages can be processed to determine if the message account that sent the inbound message is abusing the use of that message account. Additionally, outbound messages can be processed to determine if the message account that is attempting to send an outbound message is abusing the use of that message account. Each of these three processes can operate separately or in any combination with each other to further improve the probability that abusive use of a message account will be detected promptly and accurately.

Abstract: The invention relates to the discovery of novel Chondroitinase Glycoproteins (CHASEGPs), methods of manufacture, and potential uses in conditions where removal of chondroitin sulfates may be of therapeutic benefit. Chondroitinase Glycoproteins require both a substantial portion of the catalytic domain of the CHASEGP polypeptide and asparagine-linked glycosylation for optimal chondroitinase activity. The invention also includes carboxy-terminal deletion variants of CHASEGP that result in secreted variants of the protein to facilitate manufacture of a recombinant CHASEGP. Further described are suitable formulations of a substantially purified recombinant CHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. CHASEGP is useful for the degradation of glycosaminoglycans and chondroitin sulfate proteoglycans under clinical conditions where their removal is of therapeutic value.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: An information handling system (IHS) troubleshooting system includes a customer IHS including a plurality of components. A customer management system in the customer IHS detects a failure in a managed system and, in response, immediately triggers a device snapshot of the customer IHS. At least one managed system in the customer IHS includes a device snapshot engine that, in response to the customer management system triggering the device snapshot of the customer IHS, immediately create the device snapshot of the customer IHS. A device snapshot storage in the customer IHS stores the device snapshot of the customer IHS. A snapshot communication engine in the customer IHS sends the device snapshot of the customer IHS over the network to a support IHS. The support IHS may load the device snapshot into a virtual IHS and manage the virtual IHS to replicate the failure detected in the managed system for troubleshooting.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

Abstract: A datacenter management server includes a datacenter operations manager and a datacenter infrastructure manager with an infrastructure viewer and an asset deployment tool. The datacenter operations manager compiles datacenter hierarchy information for a datacenter, including identity information for a virtualized environment and identity information for a virtualization capable system. The virtualization capable system is deployed as a stand-alone system of the datacenter. The datacenter infrastructure manager receives the datacenter hierarchy information, directs the infrastructure viewer to display a hierarchical overview of the datacenter, including depictions of the virtualized environment and the virtualization capable system. The hierarchical overview is based on the identity information. The datacenter infrastructure manager also receives a selection of the depictions from a user and directs the asset deployment tool to deploy the virtualization capable system to the virtualized environment.

Abstract: An information handling system (IHS) troubleshooting system includes a customer IHS including a plurality of components. A customer management system in the customer IHS detects a failure in a managed system and, in response, immediately triggers a device snapshot of the customer IHS. At least one managed system in the customer IHS includes a device snapshot engine that, in response to the customer management system triggering the device snapshot of the customer IHS, immediately create the device snapshot of the customer IHS. A device snapshot storage in the customer IHS stores the device snapshot of the customer IHS. A snapshot communication engine in the customer IHS sends the device snapshot of the customer IHS over the network to a support IHS. The support IHS may load the device snapshot into a virtual IHS and manage the virtual IHS to replicate the failure detected in the managed system for troubleshooting.

Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.